A study of MTX110 for the treatment of the fatal childhood brain cancer DIPG
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2018
At a glance
- Drugs MTX 110 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 17 Jan 2018 New trial record
- 16 Jan 2018 According to a Midatech Pharma US media release, successful data of this trial will be used for approval of the drug from international regulators.
- 16 Jan 2018 According to a Midatech Pharma US media release, this trial will be conducted at centres in UCSF in San Francisco, and the Memorial Sloan Kettering Cancer Center in New York. First treatment in patients expected in Q1 2018. Read out from this trial expected towards the end of 2019.